StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Care sales

<< Previous

Bullboard Posts

Next >>

Comment by gojotv!on Mar 18, 2022 8:57pm

115 Views

Post# 34527187

RE:RE:Care sales

Haha, LithLover, stop it! You're confusing our idiot, braying 24/7 bashers with math, and knowledge...
All things their concave little heads can't understand, lol.
Long and strong SZLS.
It easy doubled a few months ago, and stands to easy triple (or more) by summer's end!
GLTA!

LithLover wrote: So if they continue at the same rate for Care and post another $1 million in Q4 that brings them to $4.5 million for the year in total revenue. Say for simple math (and for Liked2think's benefit) that Covid and Aristotle were only $500,000 that's $5 million total revenue for 2021.

So these would be the YTD revenue numbers for the last 5 years.

2021 $5-5.5 million
2020 $4.1 million
2019 $140,000
2018 $190,000
2017 $410,000

In the industry market valuation is between 10-15 x annual revenue. At $5-5.5 million with a 10-15 multiplier. Market cap should be in the $50-75 million range. Current market cap is $18 million.

Obviously, still in the "show me phase" and they need to continue to heavily market and continue to show increased revenues, but currently the valuation is way off at 1/3 of where it should be.

Q4/Full year 2021 comes out March 31, 2022

Q1 2022 comes out May 16, 2022

brad129 wrote: Where did we get the numbers for Care that prior to acquisition they were doing 1 million per quarter? If correct than we should see minimum 1 million on the books since we have had a full quarter of sales.